<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931982</url>
  </required_header>
  <id_info>
    <org_study_id>eudraCT: 2012-005013-38</org_study_id>
    <secondary_id>2012-005013-38</secondary_id>
    <nct_id>NCT01931982</nct_id>
  </id_info>
  <brief_title>Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.</brief_title>
  <acronym>EGOFIP</acronym>
  <official_title>Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion
      in the heart of patients with type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coronary flow reserve (CFR)</measure>
    <time_frame>CFR is measured at baseline and after 10 weeks of intervention</time_frame>
    <description>CFR can be reliably assessed non-invasively by trans-thoracic Doppler flow echocardiography of the left anterior descending artery with a success rate of over 90% even in an obese population with a relative poor acoustic window. CFR is the ratio of flow during stress to during rest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Endothelial function:</measure>
    <time_frame>Endothelial function is measured at baseline and after 10 weeks of intervention</time_frame>
    <description>Measurement of Peripheral Arterial Tone, with the use of the commercially available machine (Endo-PAT2000®) assesses the control of digital vascular tone by the sympathetic nervous system and nitric oxide (NO).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in HbA1c</measure>
    <time_frame>Measurements at baseline and after 10 weeks of intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting C-peptide</measure>
    <time_frame>C-peptide is measured at baseline and after 10 weeks of intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting insulin</measure>
    <time_frame>Fasting insulin is measured at baseline and after 10 weeks of intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>Fasting glucose is measured at baseline and after 10 weeks of intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in weight</measure>
    <time_frame>Weight is measured at baseline and after 10 weeks of intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Waist circumference is measured at baseline and after 10 weeks of intervention</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Microvascular Dysfunction</condition>
  <arm_group>
    <arm_group_label>victoza</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victoza</intervention_name>
    <arm_group_label>victoza</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy
             of metformin and sulfonylurea.

          -  Age: 25-75 years

          -  BMI&gt;25 kg/m2

          -  HbA1c 6,0-10 %

        Exclusion Criteria:

          -  Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.

          -  Haemoglobin &lt; 6.5 mmol/l

          -  Documented significant stenosis of the left anterior descending artery (LAD) at
             coronary angiography or CT-angiography or regional dysfunction documented during
             dipyridamol stress-echocardiography. If stress test at baseline shows significant
             stenosis the patient will be excluded from the study.

          -  Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue
             medicine: Theophyllin

          -  Pregnancy

          -  Severe asthma

          -  Active cancer

          -  Severe co-morbidity with limited life-expectancy

          -  Estimated glomerular filtration rate (eGFR) &lt;60 (measured at baseline)

          -  Severe hepatic co-morbidity

          -  Chronic alcohol abuse

          -  Heart failure with a left ventricular ejection fraction &lt;/= 45%

          -  Atrial fibrillation

          -  Chronic or previous acute pancreatitis

          -  Inflammatory bowel disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Zander, consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital region</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Mette Zander</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>diabetes, GLP-1, Victoza, CFR, microvascular dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

